<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: To determine the accuracy and acceptability to patients of non-endoscopic screening for <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e>, using an ingestible oesophageal sampling device (Cytosponge) coupled with immunocytochemisty for trefoil factor 3 </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN: Prospective cohort study </plain></SENT>
<SENT sid="2" pm="."><plain>SETTING: 12 UK general practices, with gastroscopies carried out in one hospital endoscopy unit </plain></SENT>
<SENT sid="3" pm="."><plain>PARTICIPANTS: 504 of 2696 eligible patients (18.7%) aged 50 to 70 years with a previous prescription for an acid suppressant (H(2) receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> or <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi>) for more than three months in the past five years </plain></SENT>
<SENT sid="4" pm="."><plain>MAIN OUTCOME MEASURES: Sensitivity and specificity estimates for detecting <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> compared with gastroscopy as the ideal method, and patient <z:hpo ids='HP_0000739'>anxiety</z:hpo> (short form Spielberger state trait <z:hpo ids='HP_0000739'>anxiety</z:hpo> inventory, impact of events scale) and acceptability (visual analogue scale) of the test </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: 501 of 504 (99%) participants (median age 62, male to female ratio 1:1.2) successfully swallowed the Cytosponge </plain></SENT>
<SENT sid="6" pm="."><plain>No serious adverse events occurred </plain></SENT>
<SENT sid="7" pm="."><plain>In total, 3.0% (15/501) had an endoscopic diagnosis of <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> (â‰¥1 cm circumferential length, median circumferential and maximal length of 2 cm and 5 cm, respectively) with <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> </plain></SENT>
<SENT sid="8" pm="."><plain>Compared with gastroscopy the sensitivity and specificity of the test was 73.3% (95% confidence interval 44.9% to 92.2%) and 93.8% (91.3% to 95.8%) for 1 cm or more circumferential length and 90.0% (55.5% to 99.7%) and 93.5% (90.9% to 95.5%) for clinically relevant segments of 2 cm or more </plain></SENT>
<SENT sid="9" pm="."><plain>Most participants (355/496, 82%, 95% confidence interval 78.9% to 85.1%) reported low levels of <z:hpo ids='HP_0000739'>anxiety</z:hpo> before the test, and scores remained within <z:mpath ids='MPATH_458'>normal</z:mpath> limits at follow-up </plain></SENT>
<SENT sid="10" pm="."><plain>Less than 4.5% (2.8% to 6.1%) of participants reported <z:e sem="disease" ids="C0815107" disease_type="Mental or Behavioral Dysfunction" abbrv="">psychological distress</z:e> a week after the procedure </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: The performance of the Cytosponge test was promising and the procedure was well tolerated </plain></SENT>
<SENT sid="12" pm="."><plain>These data bring screening for <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> into the realm of possibility </plain></SENT>
<SENT sid="13" pm="."><plain>Further evaluation is recommended </plain></SENT>
</text></document>